Search results for "bsa"

showing 10 items of 263 documents

Functional incorporation of green fluorescent protein into hepatitis B virus envelope particles

2004

AbstractThe envelope of hepatitis B virus (HBV), containing the L, M, and S proteins, is essential for virus entry and maturation. For direct visualization of HBV, we determined whether envelope assembly could accommodate the green fluorescent protein (GFP). While the C-terminal addition of GFP to S trans-dominant negatively inhibited empty envelope particle secretion, the N-terminal GFP fusion to S (GFP.S) was co-integrated into the envelope, giving rise to fluorescent particles. Microscopy and topogenesis analyses demonstrated that the proper intracellular distribution and folding of GFP.S, required for particle export were rescued by interprotein interactions with wild-type S. Thereby, a…

Hepatitis B virusRecombinant Fusion ProteinsGreen Fluorescent ProteinsRestriction MappingEnzyme-Linked Immunosorbent AssayBiologyTransfectionmedicine.disease_causeHBsAg particlesArticleViral envelopeGreen fluorescent proteinViral Envelope ProteinsViral envelopeViral entryVirologyChlorocebus aethiopsmedicineAnimalsHumansGreen fluorescent proteinSecretionPromoter Regions GeneticHepatitis B virusCOS cellsfungiTransfectionMolecular biologyCell biologyKineticsCOS CellsMetallothioneinVirus assembly and secretionProtein KinasesIntracellularVirology
researchProduct

The long-term course of chronic hepatitis B

1999

The aim of this study was to assess the long-term outcome in hepatitis B virus (HBV)-infected patients according to HBV, hepatitis C virus (HCV), and hepatitis D virus (HDV) replication, focusing on survival, liver failure, and hepatocellular carcinoma (HCC). A cohort of 302 hepatitis B surface antigen (HBsAg)-positive subjects (mean age, 34 +/- 15.3 years; male/female 214/88; 39 subjects under 14 years) with biopsy-proven chronic hepatitis (86 with cirrhosis) was prospectively assessed, with a median follow-up of 94 +/- 37.6 months. One hundred nine patients received interferon alfa (IFN). At baseline, 86 subjects (28.5%) were hepatitis B e antigen (HBeAg)-positive (wild-type HBV), 80 (26.…

Hepatitis B virusmedicine.medical_specialtyHBsAgCirrhosisHepatologybusiness.industryHepatitis C virusvirus diseasesHepatitis Bmedicine.disease_causemedicine.diseaseGastroenterologydigestive system diseasesSurgeryHBeAgInternal medicineHepatocellular carcinomamedicineHepatitis D virusbusinessHepatology
researchProduct

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study.

1994

A multicenter longitudinal study was performed to assess the survival of hepatitis B surface antigen positive compensated cirrhosis, primarily in relation to hepatitis B virus replication and hepatitis delta virus infection, and to construct a prognostic index based on entry characteristics. This cohort study involved nine university medical centers in Europe. Three hundred and sixty-six Caucasian HBsAg positive patients with cirrhosis who had never had clinical manifestations of hepatic decompensation were enrolled and followed for a mean period of 72 months (6 to 202 months). Inclusion criteria were biopsy-proven cirrhosis, information on serum hepatitis B e antigen and antibody to hepati…

Hepatitis B virusmedicine.medical_specialtyHBsAgHepatitis B virusCirrhosisHepatologybusiness.industryHepatitis B virus; cirrhosis; prognosiscirrhosismedicine.diseasemedicine.disease_causeGastroenterologyVirusHBeAgInternal medicineHepatocellular carcinomaImmunologymedicineHepatitis D virusprognosisbusinessSurvival analysis
researchProduct

Effectiveness of a screening program for HBV, HCV, and HIV infections in African migrants to Sicily

2021

BACKGROUND Migrants from Africa are vulnerable to viral infections during their journey. METHODS Migrants who arrived in western Sicily were offered early screening for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infection. A questionnaire was administered to evaluate risk factors, and antiviral therapy was offered to subjects with active infection. A multiple regression analysis and adjusted odds ratio were obtained to evaluate risk factors. RESULTS Overall, 2,639 of 2,751 (95.9%) migrants who arrived between 2015 and 2017 accepted screening and 1,911 (72.4%) completed the questionnaire. HBsAg was positive in 257 (9.7%) migrants, 24 (0.9%) were …

Hepatitis B virusmedicine.medical_specialtyHBsAgHepatitis C virusHuman immunodeficiency virus (HIV)HIV InfectionsHepacivirusmedicine.disease_causeAntiviral AgentsInternal medicinePrevalencemedicineHumansInfectious disease (athletes)SicilyTransients and MigrantsHepatitis B virusHepatitisSexual violenceHepatologybusiness.industryGastroenterologyvirus diseasesOdds ratioHepatitis C ChronicHepatitis Bmedicine.diseaseHepatitis CFemalebusinessDigestive and Liver Disease
researchProduct

e System and intrahepatocelullar HBcAG and HBsAG in HBsAG positive patients with liver diseases and healthy carriers.

1977

Patients with hepatitis-B surface antigen positive liver diseases and healthy carriers were studied for the presence of e-antigen and anti-e as well as for intrahepatocellular HBsAG and hepatitis-B core antigen. The e-antigen was demonstrated in 9 out of 12 patients with chronic perisitent hepatitis, in 15 out of 39 patients with chronic active hepatitis, in 3 out of 40 patients with acute type B hepatitis, and in 2 out of 9 patients with a protracted course of type B hepatitis. No e-antigen was found in healthy HBsAG carriers nor in patients with complete recovery from type B hepatitis one year after onset of the disease. Anti-e was detected in 24 out of 61 healthy HBsAG carriers with a no…

HepatitisHBsAgChronic Activebusiness.industryLiver cellLiver DiseasesGastroenterologyChronic persistent hepatitisDiseasemedicine.diseaseHepatitis BHepatitis B Core AntigensHepatitisHepatitis B AntigensHBcAgAntigenLiverImmunologyAcute DiseaseCarrier StateChronic DiseasemedicineHumansAntigensbusinessScandinavian journal of gastroenterology
researchProduct

Liver diseases and hepatitis B virus antigens and antibodies in chronic HBsAg carriers in childhood

1980

Liver biopsies were obtained from 109 children who had been chronic carriers of HBsAg for more than 6 months. The specimens were examined for the presen Ice of intracellular HBsAg, HBcAg and HBeAg by direct immunofluorescence. Sera were tested for HBeAg, virus B specific DNA polymerase, anti-HBs, anti-HBe and anti-HBc. On the basis of accepted histological criteria we found chronic active hepatitis (CAH) in 56 and chronic persistent hepatitis (CPH) in 19 children. 15 cases had minimal changes (minimal hepatitis, MH) and 19 normal liver tissue (healthy HBsAg carriers, HC). Children with CAH and CPH had HBeAg, DNA polymerase and anti-HBc in their serum. HBcAg and HBeAg were found in 5-50% of …

HepatitisHepatitis B virusHBsAgbiologybusiness.industryvirusesLiver cellvirus diseasesmedicine.diseasemedicine.disease_causeVirologydigestive system diseasesVirusHBcAgHBeAgPediatrics Perinatology and Child HealthImmunologybiology.proteinMedicineAntibodybusinessPediatric Research
researchProduct

Hepatitis B Virus Reactivation and Alemtuzumab Therapy.

2004

Abstract Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for haematological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 on lymphoid cells, produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed a full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab. Lam…

HepatitisHepatitis B virusHBsAgmedicine.diagnostic_testCD52business.industryImmunologyvirus diseasesLamivudineCell BiologyHematologyHepatitis Bmedicine.diseasemedicine.disease_causeBiochemistrydigestive system diseasesLiver biopsyImmunologymedicineAlemtuzumabbusinessmedicine.drugBlood
researchProduct

Viral Hepatitis — An Update

1983

In 1973, Feinstone and co-workers [52] were the first to report the visualization of virus-like particles by immune electron microscopy in acute phase stool specimens of human volunteers who developed hepatitis following inoculation with MS-1 strain of hepatitis A virus [18]. Soon thereafter morphologically identical particles were recovered from the stool of individuals acquiring hepatitis during natural outbreaks of the disease [39, 64].

HepatitisImmune systembusiness.industryImmune serum globulinDane ParticlemedicineOutbreakHbsag carriermedicine.diseaseViral hepatitisbusinessVirologyHepatitis a virus
researchProduct

The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers.

1994

As a putative mechanism of hepatitis B virus (HBV) uptake into hepatocytes the interaction between HBV and the hepatic, human-derived asialoglycoprotein receptor (ASGPR) was investigated. Sera from patients with different variations of hepatitis B surface antigen-(HBsAg) positive chronic hepatitis, HBV particles isolated from HBV carriers with high-titre viraemia and commercial HBsAg served as sources of HBV. ASGPR was affinity-purified from human liver. HBV that had bound to isolated ASGPR was either detected by radio-immunoassay using solid-phase bound ASGPR or enzyme immunoassay with biotin-ASGPR bound to immobilized HBV. Furthermore, binding and uptake of purified, 125I-labelled HBV par…

HepatoblastomaHBsAgHepatitis B virusCarcinoma HepatocellularAsialoglycoproteinsReceptors Cell SurfaceAsialoglycoprotein Receptormedicine.disease_causeBinding CompetitiveVirusVirologymedicineTumor Cells CulturedHumansHepatitis B e AntigensViremiaBinding siteHepatitis B virusCOS cellsHepatitis B Surface AntigensbiologyCell MembraneLiver Neoplasmsvirus diseasesBlood ProteinsHepatitis Bmedicine.diseaseHepatitis BVirologyMolecular biologydigestive system diseasesLiverAcute DiseaseCarrier StateChronic Diseasebiology.proteinReceptors VirusAsialoglycoprotein receptorAntibodyThe Journal of general virology
researchProduct

Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S01688278173…

2018

It has come to our attention that the PITER framework investigator, Alessandro Federico, was incorrectly listed as F. Alessandro in the original manuscript. Please note that the correct name of this author is Alessandro Federico (2nd University of Naples). The correct list of PITER investigators is in the footnote below.

HepatologyHepatitis B; EASL guidelines; Treatment; Interferon; Entecavir; Tenofovir; TAF; HBsAg; Hepatocellular carcinoma; HBV DNA; HBV reactivation; Mother to child transmissionHepatocellular carcinomaHBV reactivationEASL guidelinesHepatitis BEntecavirTreatmentHBsAgTAFHBV DNAMother to child transmissionInterferonTenofovirEASL guideline
researchProduct